Stay updated with breaking news from Simrit Parmar. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO, "GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing,...
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!
Author of the article: Nick Lees • Edmonton Journal Publishing date: May 02, 2021 • 2 hours ago • 3 minute read • UPLOADED BY: Nick Lees ::: EMAIL: nleesyeg@gmail.com ::: PHONE: 7804823603 ::: CREDIT: Supplied ::: CAPTION: Global TV anchor and producer Gord Steinke and his wife Deb have enjoyed motorbike trips in the Rockies during the COVID-19 pandemic and are pictured here taking a break at the north end of Jasper's Medicine Lake. When the going is safe, the couple plan to trace family roots in England before visiting First World One French battle sites where S...
Incyte and Cellenkos Enter into Global Development Collaboration Agreement for CK0804 WILMINGTON, Del.--(Business Wire)--Incyte (Nasdaq:INCY) and Cellenkos, Inc., a privately held, clinical stage biotech company, today announced a development collaboration to investigate the combination of ruxolitinib (Jakafi ®) and CK0804, Cellenkos’ cryopreserved CXCR4 enriched, allogeneic, umbilical cord blood-derived T-regulatory cells, in patients with myelofibrosis (MF). In addition, Incyte has an exclusive option to acquire sole rights to develop and commercialize CK0804, and genetically-modified ...
®) and CK0804, cord blood-derived T-regulatory cells, in patients with myelofibrosis - WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte (Nasdaq:INCY) and Cellenkos, Inc., a privately held, clinical stage biotech company, today announced a development collaboration to investigate the combination of ruxolitinib (Jakafi ®) and CK0804, Cellenkos’ cryopreserved CXCR4 enriched, allogeneic, umbilical cord blood-derived T-regulatory cells, in patients with myelofibrosis (MF). In addition, Incyte has an exclusive option to acquire sole rights to develop and commercialize CK0804, and genetically-mod...